Traumatic brain injury (TBI) remains one of the leading causes of morbidity and mortality
amongst civilians and military personnel globally. Despite advances in our knowledge of the …

Alzheimer's disease (AD) affects an estimated 44 million individuals worldwide, yet no
therapeutic intervention is available to stop the progression of the dementia …

Minocycline is a second‐generation, semi‐synthetic tetracycline that has been in therapeutic
use for over 30 years because of its antibiotic properties against both gram‐positive and …

Microglia are activated in response to a number of different pathological states within the
CNS including injury, ischemia, and infection. Microglial activation results in their production …

Alzheimer's disease is the most common cause of dementia in elderly people. Research into
Alzheimer's disease therapy has been at least partly successful in terms of developing …

Background: Microglial activation is a hallmark of neuroinflammation, seen in most acute
and chronic neuropsychiatric conditions. With growing knowledge about microglia functions …

Alzheimer's disease (AD), the most common chronic and progressive neurodegenerative
disorder, is characterized by extracellular deposits of amyloid β‐peptides (Aβ) and …

This review focuses on research in epidemiology, neuropathology, molecular biology, and
genetics regarding the hypothesis that pathogens interact with susceptibility genes and are …

Chronic pain often occurs in the elderly, particularly in the patients with neurodegenerative
disorders such as Alzheimer's disease (AD). Although studies indicate that chronic pain …

Covering: up to 2010 This review focuses on recent developments in the use of natural
products as therapeutics for Alzheimer's disease. The compounds span a diverse array of …